Cleveland BioLabs Stock Price, News & Analysis (NASDAQ:CBLI)

$3.38 0.18 (5.63 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$3.20
Today's Range$3.02 - $3.38
52-Week Range$1.22 - $5.55
Volume74,200 shs
Average Volume397,855 shs
Market Capitalization$36.10 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.32

About Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs logoCleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBLI
CUSIPN/A
Phone716-849-6810

Debt

Debt-to-Equity RatioN/A
Current Ratio4.77%
Quick Ratio4.77%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.52 million
Price / Sales10.83
Cash FlowN/A
Price / CashN/A
Book Value$1.17 per share
Price / Book2.89

Profitability

Trailing EPS($0.87)
Net Income$-2,650,000.00
Net Margins-472.44%
Return on Equity-91.87%
Return on Assets-73.83%

Miscellaneous

Employees25
Outstanding Shares11,280,000

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.11) earnings per share for the quarter. The biotechnology company had revenue of $0.30 million for the quarter. Cleveland BioLabs had a negative return on equity of 91.87% and a negative net margin of 472.44%. View Cleveland BioLabs' Earnings History.

Who are some of Cleveland BioLabs' key competitors?

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the folowing people:

  • Langdon L. Miller M.D., President (Age 63)
  • Yakov N. Kogan Ph.D., Chief Executive Officer, Principal Financial Officer (Age 43)
  • Andrei V. Gudkov Ph.D., Chief Scientific Officer (Age 60)
  • Alexander Andryushechkin, Independent Director (Age 33)
  • Anna Evdokimova, Independent Director (Age 41)
  • Alexey Nechaev, Independent Director (Age 29)
  • Ivan Persiyanov, Independent Director (Age 37)
  • Randy S. Saluck J.D., Independent Director (Age 51)

How do I buy Cleveland BioLabs stock?

Shares of Cleveland BioLabs can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of Cleveland BioLabs stock can currently be purchased for approximately $3.38.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $36.10 million and generates $3.52 million in revenue each year. The biotechnology company earns $-2,650,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Cleveland BioLabs employs 25 workers across the globe.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]


MarketBeat Community Rating for Cleveland BioLabs (CBLI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cleveland BioLabs (NASDAQ:CBLI) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Cleveland BioLabs (NASDAQ:CBLI) Earnings History and Estimates Chart

Earnings by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs (NASDAQ CBLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.11)$0.30 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.50)$0.21 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.15)$0.58 millionViewN/AView Earnings Details
2/22/2017Q4 2016($0.11)$0.99 millionViewN/AView Earnings Details
8/15/2016Q2($0.17)$0.58 millionViewN/AView Earnings Details
5/16/2016Q116($0.06)$0.81 millionViewN/AView Earnings Details
11/5/2015Q315$0.31$415.00 million$0.50 millionViewN/AView Earnings Details
8/12/2015Q215($0.72)$562.10 million$329.90 millionViewListenView Earnings Details
5/6/2015Q115($1.14)$1.33 million$0.61 millionViewN/AView Earnings Details
2/24/2015Q114($1.02)$3.87 million$1.39 millionViewN/AView Earnings Details
3/11/2014Q413($0.12)($0.01)$1.74 million$3.87 millionViewN/AView Earnings Details
11/6/2013Q313($0.14)($0.09)$1.61 million$1.60 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.16)($0.07)$1.48 million$1.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.17)($0.22)$1.73 million$1.37 millionViewN/AView Earnings Details
11/8/2012Q312($0.02)($0.30)$23.87 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cleveland BioLabs (NASDAQ:CBLI) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cleveland BioLabs (NASDAQ:CBLI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cleveland BioLabs (NASDAQ CBLI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.44%
Institutional Ownership Percentage: 4.36%
Insider Trades by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs (NASDAQ CBLI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/25/2015Randy S SaluckDirectorBuy1,891$3.42$6,467.22View SEC Filing  
5/21/2013Paul E DicorletoDirectorBuy6,210$1.61$9,998.10View SEC Filing  
5/17/2013Randy S SaluckDirectorBuy3,500$1.60$5,600.00View SEC Filing  
3/15/2013James AntalDirectorBuy3,700$1.56$5,772.00View SEC Filing  
9/21/2012James AntalDirectorBuy2,316$2.60$6,021.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cleveland BioLabs (NASDAQ CBLI) News Headlines

Source:
DateHeadline
ETFs with exposure to Cleveland BioLabs, Inc. : December 13, 2017ETFs with exposure to Cleveland BioLabs, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 5:08 PM
Cleveland BioLabs (CBLI) versus The Competition Critical ReviewCleveland BioLabs (CBLI) versus The Competition Critical Review
www.americanbankingnews.com - December 5 at 9:26 PM
Cleveland BioLabs (CBLI) Stock Rating Lowered by ValuEngineCleveland BioLabs (CBLI) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 3 at 7:58 PM
ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 4:57 PM
Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:00 AM
What Does Cleveland BioLabs Inc’s (CBLI) Ownership Structure Look Like?What Does Cleveland BioLabs Inc’s (CBLI) Ownership Structure Look Like?
finance.yahoo.com - November 22 at 10:44 PM
ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017
finance.yahoo.com - November 16 at 12:26 PM
Cleveland BioLabs, Inc. (CBLI) Posts Quarterly  Earnings ResultsCleveland BioLabs, Inc. (CBLI) Posts Quarterly Earnings Results
www.americanbankingnews.com - November 15 at 12:56 PM
Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development ProgressCleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress
finance.yahoo.com - November 14 at 5:29 PM
Financial Contrast: Cleveland BioLabs (CBLI) versus Its PeersFinancial Contrast: Cleveland BioLabs (CBLI) versus Its Peers
www.americanbankingnews.com - November 13 at 11:28 AM
How Does Cleveland BioLabs Inc (CBLI) Compare To The Healthcare Sector?How Does Cleveland BioLabs Inc (CBLI) Compare To The Healthcare Sector?
finance.yahoo.com - November 8 at 7:59 PM
ETFs with exposure to Cleveland BioLabs, Inc. : October 26, 2017ETFs with exposure to Cleveland BioLabs, Inc. : October 26, 2017
finance.yahoo.com - October 26 at 5:11 PM
Head to Head Survey: Curis (CRIS) and Cleveland BioLabs (CBLI)Head to Head Survey: Curis (CRIS) and Cleveland BioLabs (CBLI)
www.americanbankingnews.com - October 13 at 8:32 PM
ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 6:31 PM
ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 10:01 PM
Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 5:17 PM
Contrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST)Contrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST)
www.americanbankingnews.com - September 17 at 2:31 AM
What You Must Know About Cleveland BioLabs Inc’s (CBLI) RisksWhat You Must Know About Cleveland BioLabs Inc’s (CBLI) Risks
finance.yahoo.com - September 11 at 5:34 PM
Cleveland BioLabs, Inc. (CBLI) Posts  Earnings ResultsCleveland BioLabs, Inc. (CBLI) Posts Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market PotentialCleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential
finance.yahoo.com - August 11 at 5:26 PM
ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 10:18 PM
ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:35 PM
Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development ProgressCleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress
feeds.benzinga.com - May 15 at 8:01 AM
Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX...Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX...
www.finanznachrichten.de - April 19 at 11:03 PM
Cleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-PlusCleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-Plus
investorplace.com - April 19 at 3:33 PM
Cleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA ReviewCleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA Review
www.streetinsider.com - April 19 at 1:01 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
biz.yahoo.com - February 22 at 9:21 PM
Cleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoDCleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoD
www.streetinsider.com - October 12 at 8:37 AM
BRIEF-Cleveland BioLabs announces a $1.1 mln cost realignment with Department of DefenseBRIEF-Cleveland BioLabs announces a $1.1 mln cost realignment with Department of Defense
www.reuters.com - October 11 at 4:13 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal OfficersCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - July 22 at 4:22 PM
CLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StaCLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta
biz.yahoo.com - July 21 at 6:05 AM
CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StandCLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
biz.yahoo.com - July 12 at 4:25 PM
22nd Century to begin cannabis research at new medical campus labs22nd Century to begin cannabis research at new medical campus labs
www.bizjournals.com - May 12 at 2:40 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
biz.yahoo.com - May 6 at 5:55 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersCLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - April 15 at 3:05 PM
GLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A SnagGLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag
www.rttnews.com - March 17 at 2:04 AM
CLEVELAND BIOLABS INC Files SEC form 8-K, Other EventsCLEVELAND BIOLABS INC Files SEC form 8-K, Other Events
biz.yahoo.com - March 16 at 2:50 PM
Hottest Services Stocks Now – CAI NEWT INST MOBLHottest Services Stocks Now – CAI NEWT INST MOBL
investorplace.com - March 8 at 11:42 AM
CLEVELAND BIOLABS INC Files SEC form 10-K, Annual ReportCLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 23 at 5:04 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial ConditionCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - February 22 at 10:35 AM
Cleveland BioLabs, Inc. (CBLI)Cleveland BioLabs, Inc. (CBLI)
biz.yahoo.com - February 18 at 6:31 PM
Hottest Services Stocks Now – ADUS SREV EBIX CBLIHottest Services Stocks Now – ADUS SREV EBIX CBLI
investorplace.com - February 9 at 10:47 AM
Cleveland Biolabs (CBLI) Says Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell AxisCleveland Biolabs (CBLI) Says Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis
www.streetinsider.com - February 9 at 10:47 AM

SEC Filings

Cleveland BioLabs (NASDAQ:CBLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cleveland BioLabs (NASDAQ:CBLI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cleveland BioLabs (NASDAQ CBLI) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.